Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04057053 · ClinicalTrials.gov registry record · Early Phase 1

Netarsudil Use After Descemetorhexis Without Endothelial Keratoplasty

A Early Phase 1 study of Cataract and Fuchs Endothelial Dystrophy, sponsored by Massachusetts Eye and Ear Infirmary.

Completed
Registry status
Early Phase 1
Development phase
10
Enrollment target
1
Study location

NCT04057053: Completed Early Phase 1 study of Cataract and Fuchs Endothelial Dystrophy, sponsored by Massachusetts Eye and Ear Infirmary.

NCT04057053 is a Early Phase 1 study of Cataract and Fuchs Endothelial Dystrophy that has completed, run by Massachusetts Eye and Ear Infirmary. The registered enrollment target is 10 participants, below the 228-participant average among 83 other Cataract trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04057053, a Early Phase 1 study of Cataract and Fuchs Endothelial Dystrophy, has completed, sponsored by Massachusetts Eye and Ear Infirmary.

COMPLETED
Registry status
Early Phase 1
Development phase
10 participants
Enrollment target
1
Study location

Study Summary

Primary aim of the study is to determine whether a rho kinase inhibitor, Netarsudil, can speed corneal clearance after DWEK. Secondary aim of the study is to investigate whether patient factors, such as baseline age, pachymetry, or endothelial cell count influence response to Netarsudil.

Interventions

  • DRUG Netarsudil 0.02% Ophthalmic Solution

Study Locations (1)

Massachusetts

  • Massachusetts Eye and Ear Infirmary - Boston

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2018-10-02
Est. Completion 2020-12-20
Phase Early Phase 1

What the finished NCT04057053 record still lists

NCT04057053 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 228-participant average among 83 other Cataract trials with a reported enrollment target (96% lower).

The record links to 2 conditions, with Cataract appearing as the primary indexed condition, and to 1 intervention - of which Netarsudil 0.02% Ophthalmic Solution is the first listed.

NCT04057053 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT04057053 about?

NCT04057053 is a clinical study titled "Netarsudil Use After Descemetorhexis Without Endothelial Keratoplasty". Primary aim of the study is to determine whether a rho kinase inhibitor, Netarsudil, can speed corneal clearance after DWEK. Secondary aim of the study is to investigate whether patient factors, such as baseline age, pachymetry, or endothelial cell count influence response to Netarsudil.

What is the current status of trial NCT04057053?

This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 10 participants. The study started on 2018-10-02. Estimated completion is 2020-12-20.

What conditions does trial NCT04057053 study?

This clinical trial studies the following conditions: Cataract, Fuchs Endothelial Dystrophy.

What interventions are being tested in trial NCT04057053?

The interventions under investigation include: Netarsudil 0.02% Ophthalmic Solution (DRUG).

Who is sponsoring clinical trial NCT04057053?

This trial is sponsored by Massachusetts Eye and Ear Infirmary, which has 73 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04057053 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cataract

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04057053's enrollment target sits among peer trials

10 83rd of 83 the lowest of 83 other Cataract trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Cataract trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00623389 · 10 participants · NA

    Evaluation of an Advanced Lower Extremity Neuroprostheses

  • NCT01241864 · 10 participants · Phase 2

    Islet Transplantation in Type 1 Diabetic Kidney Allograft

  • NCT01293214 · 10 participants · NA

    Vascularized Composite Allotransplantation for Multiple Extremity Amputations

  • NCT01474148 · 10 participants · NA

    A Neuroprosthesis for Seated Posture and Balance

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04057053, the US trial registry maintained by the National Library of Medicine. NCT04057053 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.